213 related articles for article (PubMed ID: 12011121)
1. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
Kornblith AB; Herndon JE; Silverman LR; Demakos EP; Odchimar-Reissig R; Holland JF; Powell BL; DeCastro C; Ellerton J; Larson RA; Schiffer CA; Holland JC
J Clin Oncol; 2002 May; 20(10):2441-52. PubMed ID: 12011121
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
4. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
[TBL] [Abstract][Full Text] [Related]
5. Azacitidine: in myelodysplastic syndromes.
Siddiqui MA; Scott LJ
Drugs; 2005; 65(13):1781-9; discussion 1790-1. PubMed ID: 16114977
[TBL] [Abstract][Full Text] [Related]
6. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
Hatoum HT; Lin SJ; Buchner D; Kim E
Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
[TBL] [Abstract][Full Text] [Related]
7. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.
Prebet T; Sun Z; Figueroa ME; Ketterling R; Melnick A; Greenberg PL; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Litzow M; Gabrilove J; Erba HP; Gore SD; Tallman MS
J Clin Oncol; 2014 Apr; 32(12):1242-8. PubMed ID: 24663049
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
Adès L; Itzykson R; Fenaux P
Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
[TBL] [Abstract][Full Text] [Related]
9. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M; Suciu S; Baila L; Rüter BH; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Beeldens F; Muus P; Pflüger KH; Coens C; Hagemeijer A; Eckart Schaefer H; Ganser A; Aul C; de Witte T; Wijermans PW
J Clin Oncol; 2011 May; 29(15):1987-96. PubMed ID: 21483003
[TBL] [Abstract][Full Text] [Related]
10. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
12. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
[TBL] [Abstract][Full Text] [Related]
13. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group.
Papageorgiou SG; Kontos CK; Kotsianidis I; Vasilatou D; Symeonidis A; Galanopoulos A; Bouchla A; Hatzimichael E; Repousis P; Zikos P; Viniou NA; Poulakidas E; Vassilakopoulos TP; Diamantopoulos P; Diamantopoulos MA; Mparmparousi D; Bouronikou E; Papadaki H; Panayiotidis P; Pappa V
Hematol Oncol; 2018 Oct; 36(4):693-700. PubMed ID: 30129144
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.
Ritchie EK
Clin Interv Aging; 2012; 7():165-73. PubMed ID: 22791989
[TBL] [Abstract][Full Text] [Related]
15. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
[TBL] [Abstract][Full Text] [Related]
16. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine.
Abáigar M; Ramos F; Benito R; Díez-Campelo M; Sánchez-del-Real J; Hermosín L; Rodríguez JN; Aguilar C; Recio I; Alonso JM; de las Heras N; Megido M; Fuertes M; del Cañizo MC; Hernández-Rivas JM
Ann Hematol; 2013 Nov; 92(11):1543-52. PubMed ID: 23740492
[TBL] [Abstract][Full Text] [Related]
18. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.
Buckstein R; Yee K; Wells RA;
Cancer Treat Rev; 2011 Apr; 37(2):160-7. PubMed ID: 20591575
[TBL] [Abstract][Full Text] [Related]
19. Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D; Filanovsky K; Gafter-Gvili A; Vidal L; Aviv A; Gatt ME; Silbershatz I; Herishanu Y; Arad A; Tadmor T; Dally N; Nemets A; Rouvio O; Ronson A; Herzog-Tzarfati K; Akria L; Braester A; Hellmann I; Yeganeh S; Nagler A; Leiba R; Mittelman M; Ofran Y
Am J Hematol; 2013 Feb; 88(2):130-4. PubMed ID: 23345248
[TBL] [Abstract][Full Text] [Related]
20. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group.
Lübbert M; Suciu S; Hagemeijer A; Rüter B; Platzbecker U; Giagounidis A; Selleslag D; Labar B; Germing U; Salih HR; Muus P; Pflüger KH; Schaefer HE; Bogatyreva L; Aul C; de Witte T; Ganser A; Becker H; Huls G; van der Helm L; Vellenga E; Baron F; Marie JP; Wijermans PW;
Ann Hematol; 2016 Jan; 95(2):191-9. PubMed ID: 26596971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
